{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:46:29Z","timestamp":1791744389719,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03322-3","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T10:43:36Z","timestamp":1779619416000},"page":"1760-1776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation patients on dialysis: A systematic review and meta-analysis of randomized controlled trials and real-world evidence"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2874-2641","authenticated-orcid":false,"given":"Omar","family":"Shaheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4033-6884","authenticated-orcid":false,"given":"Mohamed","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2941-5816","authenticated-orcid":false,"given":"Ibrahem Attiya.","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1108-6764","authenticated-orcid":false,"given":"Abdelrahman Ahmed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9203-5107","authenticated-orcid":false,"given":"Omar","family":"Kassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9431-5259","authenticated-orcid":false,"given":"Ahmed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3647-5044","authenticated-orcid":false,"given":"Samer Sameh","family":"Bedwany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badria Atef Ebrahim","family":"Elhalawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6552-4900","authenticated-orcid":false,"given":"Rehab Adel","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"3","key":"3322_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ki.2009.144","volume":"76","author":"PG Korantzopoulos","year":"2009","unstructured":"Korantzopoulos PG, Goudevenos JA (2009) Atrial fibrillation in end-stage renal disease: an emerging problem. Kidney Int. 76(3):247\u2013249. https:\/\/doi.org\/10.1038\/ki.2009.144","journal-title":"Kidney Int."},{"issue":"4","key":"3322_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/rth2.12250","volume":"3","author":"O K\u00f6nigsbr\u00fcgge","year":"2019","unstructured":"K\u00f6nigsbr\u00fcgge O, Ay C (2019) Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation. Res Pract Thromb Haemost 3(4):578\u2013588. https:\/\/doi.org\/10.1002\/rth2.12250","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"3322_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.123.010595","volume":"17","author":"GY Heo","year":"2024","unstructured":"Heo GY et al (2024) \u201cAdequacy of dialysis and incidence of atrial fibrillation in patients undergoing hemodialysis.,.\u201d Circ Cardiovasc Qual Outcomes 17(8):e010595. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.123.010595","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"3322_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.23876\/j.krcp.2018.37.2.103","volume":"37","author":"MG Kiuchi","year":"2018","unstructured":"Kiuchi MG (2018) Atrial fibrillation and chronic kidney disease: a bad combination. Kidney Res Clin Pract 37(2):103\u2013105. https:\/\/doi.org\/10.23876\/j.krcp.2018.37.2.103","journal-title":"Kidney Res Clin Pract"},{"issue":"Suppl 4","key":"3322_CR5","doi-asserted-by":"publisher","first-page":"i72","DOI":"10.1093\/ckj\/sfab192","volume":"14","author":"B Canaud","year":"2021","unstructured":"Canaud B, Stephens MP, Nikam M, Etter M, Collins A (2021) \u201cMultitargeted interventions to reduce dialysis-induced systemic stress.,.\u201d Clin Kidney J 14(Suppl 4):i72\u2013i84. https:\/\/doi.org\/10.1093\/ckj\/sfab192","journal-title":"Clin Kidney J"},{"issue":"7","key":"3322_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","volume":"367","author":"JB Olesen","year":"2012","unstructured":"Olesen JB et al (2012) \u201cStroke and bleeding in atrial fibrillation with chronic kidney disease.,.\u201d N Engl J Med 367(7):625\u2013635. https:\/\/doi.org\/10.1056\/NEJMoa1105594","journal-title":"N Engl J Med"},{"issue":"9990","key":"3322_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","volume":"386","author":"FWA Verheugt","year":"2015","unstructured":"Verheugt FWA, Granger CB (2015) \u201cOral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.,.\u201d Lancet 386(9990):303\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(15)60245-8","journal-title":"Lancet"},{"issue":"8","key":"3322_CR8","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","volume":"27","author":"DK Rose","year":"2018","unstructured":"Rose DK, Bar B (2018) \u201cDirect oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents.,.\u201d J Stroke Cerebrovasc Dis 27(8):2049\u20132058. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.04.004","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"22","key":"3322_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026723","volume":"11","author":"AM Navar","year":"2022","unstructured":"Navar AM et al (2022) \u201cTrends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020.,.\u201d J Am Heart Assoc 11(22):e026723. https:\/\/doi.org\/10.1161\/JAHA.122.026723","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"3322_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB et al (2011) \u201cApixaban versus warfarin in patients with atrial fibrillation.,.\u201d N Engl J Med 365(11):981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"issue":"10","key":"3322_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10):883\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"3322_CR12","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12):1139\u20131151. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"3322_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"3322_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5853\/jos.2020.01886","volume":"22","author":"N Goel","year":"2020","unstructured":"Goel N, Jain D, Haddad DB, Shanbhogue D (2020) \u201cAnticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences.,.\u201d J Stroke 22(3):306\u2013316. https:\/\/doi.org\/10.5853\/jos.2020.01886","journal-title":"J Stroke"},{"issue":"8","key":"3322_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034176","volume":"13","author":"T-W Kao","year":"2024","unstructured":"Kao T-W, Chen Z-W, Lin Y-H (2024) \u201cAnticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis.,.\u201d J Am Heart Assoc 13(8):e034176. https:\/\/doi.org\/10.1161\/JAHA.123.034176","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"3322_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jacc.2020.01.019","volume":"75","author":"SD Pokorney","year":"2020","unstructured":"Pokorney SD et al (2020) Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and end-stage renal disease. J. Am. Coll. Cardiol. 75(11):1299\u20131308. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"3322_CR17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ndt\/gfab197","volume":"37","author":"I Zamberg","year":"2022","unstructured":"Zamberg I et al (2022) Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 37(7):1289\u20131301. https:\/\/doi.org\/10.1093\/ndt\/gfab197","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3322_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.ajkd.2013.02.381","volume":"62","author":"KP Ng","year":"2013","unstructured":"Ng KP, Edwards NC, Lip GYH, Townend JN, Ferro CJ (2013) Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis 62(3):615\u2013632. https:\/\/doi.org\/10.1053\/j.ajkd.2013.02.381","journal-title":"Am J Kidney Dis"},{"key":"3322_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.08.020","volume":"119","author":"I Kyriakoulis","year":"2024","unstructured":"Kyriakoulis I et al (2024) Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: a systematic review and meta-analysis. Eur J Intern Med 119:45\u201352. https:\/\/doi.org\/10.1016\/j.ejim.2023.08.020","journal-title":"Eur J Intern Med"},{"issue":"5","key":"3322_CR20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.hrthm.2025.02.009","volume":"22","author":"E Bulh\u00f5es","year":"2025","unstructured":"Bulh\u00f5es E et al (2025) Efficacy and safety of DOACs vs vitamin K antagonists in patients with atrial fibrillation and chronic kidney disease undergoing hemodialysis: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Heart Rhythm 22(5):1210\u20131217. https:\/\/doi.org\/10.1016\/j.hrthm.2025.02.009","journal-title":"Heart Rhythm"},{"key":"3322_CR21","doi-asserted-by":"publisher","unstructured":"Li T et al (2025) Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-025-02711-7","DOI":"10.1007\/s00392-025-02711-7"},{"key":"3322_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"issue":"10","key":"3322_CR23","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10(10):ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3322_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"issue":"5","key":"3322_CR25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10557-020-07108-4","volume":"35","author":"L-C See","year":"2021","unstructured":"See L-C et al (2021) Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis. Cardiovasc Drugs Ther 35(5):975\u2013986. https:\/\/doi.org\/10.1007\/s10557-020-07108-4","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"3322_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3322_CR27","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J. Thromb. Haemost. 13(11):2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J. Thromb. Haemost."},{"key":"3322_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3322_CR29","unstructured":"Ottawa Hospital Research Institute (accessed Jul 04, 2025) https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"3322_CR30","doi-asserted-by":"publisher","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH (2012) Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. J Stat Softw 49(5). https:\/\/doi.org\/10.18637\/jss.v049.i05","DOI":"10.18637\/jss.v049.i05"},{"issue":"2","key":"3322_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Systematic Reviews 18(2):e1230. https:\/\/doi.org\/10.1002\/cl2.1230","journal-title":"Campbell Systematic Reviews"},{"issue":"5","key":"3322_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1681\/ASN.0000000000000495","volume":"36","author":"Z Harel","year":"2025","unstructured":"Harel Z et al (2025) Anticoagulation for patients with atrial fibrillation receiving dialysis: a pilot randomized controlled trial. J. Am. Soc. Nephrol. 36(5):901\u2013910. https:\/\/doi.org\/10.1681\/ASN.0000000000000495","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"3322_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","volume":"147","author":"H Reinecke","year":"2023","unstructured":"Reinecke H et al (2023) A randomized controlled trial comparing apixaban with the Vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 147(4):296\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062779","journal-title":"Circulation"},{"issue":"23","key":"3322_CR34","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 146(23):1735\u20131745. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054990","journal-title":"Circulation"},{"issue":"6","key":"3322_CR35","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","volume":"32","author":"AS De Vriese","year":"2021","unstructured":"De Vriese AS, Caluw\u00e9 R, Van Der Meersch H, De Boeck K, De Bacquer D (2021) Safety and efficacy of Vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J. Am. Soc. Nephrol. 32(6):1474\u20131483. https:\/\/doi.org\/10.1681\/ASN.2020111566","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"3322_CR36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.hrthm.2025.01.045","volume":"22","author":"M-J Wu","year":"2025","unstructured":"Wu M-J, Chen H-H, Chen C-H, Tsai S-F (2025) Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease. Heart Rhythm 22(5):1197\u20131209. https:\/\/doi.org\/10.1016\/j.hrthm.2025.01.045","journal-title":"Heart Rhythm"},{"issue":"4S","key":"3322_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102160","volume":"64","author":"M Moore","year":"2024","unstructured":"Moore M, Vizcaino K, Ewing JA, St Ville M (2024) Reprint of: efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis. J Am Pharm Assoc (2003) 64(4S):102160. https:\/\/doi.org\/10.1016\/j.japh.2024.102160","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"3322_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65541-z","volume":"14","author":"J-H Roh","year":"2024","unstructured":"Roh J-H et al (2024) Direct oral anticoagulants for oral anticoagulants-na\u00efve Asian patients with atrial fibrillation and end-stage renal disease undergoing dialysis. Sci Rep 14(1):14679. https:\/\/doi.org\/10.1038\/s41598-024-65541-z","journal-title":"Sci Rep"},{"issue":"10","key":"3322_CR39","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/ndt\/gfae042","volume":"39","author":"SM Laville","year":"2024","unstructured":"Laville SM et al (2024) Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis. Nephrol Dial Transplant 39(10):1662\u20131671. https:\/\/doi.org\/10.1093\/ndt\/gfae042","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3322_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1053\/j.ajkd.2022.03.007","volume":"80","author":"JB Wetmore","year":"2022","unstructured":"Wetmore JB, Weinhandl ED, Yan H, Reyes JL, Herzog CA, Roetker NS (2022) Apixaban dosing patterns versus warfarin in patients with nonvalvular atrial fibrillation receiving dialysis: a retrospective cohort study. Am J Kidney Dis 80(5):569-579.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.03.007","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"3322_CR41","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","volume":"138","author":"KC Siontis","year":"2018","unstructured":"Siontis KC et al (2018) Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 138(15):1519\u20131529. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035418","journal-title":"Circulation"},{"issue":"2","key":"3322_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/rth2.12083","volume":"2","author":"D Reed","year":"2018","unstructured":"Reed D, Palkimas S, Hockman R, Abraham S, Le T, Maitland H (2018) Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2(2):291\u2013298. https:\/\/doi.org\/10.1002\/rth2.12083","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"3322_CR43","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","volume":"131","author":"KE Chan","year":"2015","unstructured":"Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW (2015) Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131(11):972\u2013979. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014113","journal-title":"Circulation"},{"issue":"1","key":"3322_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"3322_CR45","unstructured":"Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis | Cochrane. (accessed Sep 13, 2025) https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-13#_ENREF_42"},{"issue":"7109","key":"3322_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"issue":"11","key":"3322_CR47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/heartjnl-2016-309266","volume":"103","author":"F Yang","year":"2017","unstructured":"Yang F et al (2017) Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 103(11):818\u2013826. https:\/\/doi.org\/10.1136\/heartjnl-2016-309266","journal-title":"Heart"},{"issue":"3","key":"3322_CR48","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ki.2013.399","volume":"85","author":"CK Yeung","year":"2014","unstructured":"Yeung CK, Shen DD, Thummel KE, Himmelfarb J (2014) Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 85(3):522\u2013528. https:\/\/doi.org\/10.1038\/ki.2013.399","journal-title":"Kidney Int"},{"issue":"3","key":"3322_CR49","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.19102\/icrm.2017.080302","volume":"8","author":"JA Reiffel","year":"2017","unstructured":"Reiffel JA (2017) Time in the therapeutic range (TTR): an overly simplified conundrum. J Innov Card Rhythm Manag 8(3):2643\u20132646. https:\/\/doi.org\/10.19102\/icrm.2017.080302","journal-title":"J Innov Card Rhythm Manag"},{"issue":"1","key":"3322_CR50","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA et al (2024) 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 149(1):e1\u2013e156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193","journal-title":"Circulation"},{"issue":"36","key":"3322_CR51","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC et al (2024) 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45(36):3314\u20133414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"issue":"11","key":"3322_CR52","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1681\/ASN.2015091065","volume":"27","author":"SU Nigwekar","year":"2016","unstructured":"Nigwekar SU et al (2016) A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol 27(11):3421\u20133429. https:\/\/doi.org\/10.1681\/ASN.2015091065","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3322_CR53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1053\/j.ajkd.2022.06.011","volume":"81","author":"B Gallo Marin","year":"2023","unstructured":"Gallo Marin B, Aghagoli G, Hu SL, Massoud CM, Robinson-Bostom L (2023) Calciphylaxis and kidney disease: A review. Am J Kidney Dis 81(2):232\u2013239. https:\/\/doi.org\/10.1053\/j.ajkd.2022.06.011","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"3322_CR54","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMra1505292","volume":"378","author":"SU Nigwekar","year":"2018","unstructured":"Nigwekar SU, Thadhani R, Brandenburg VM (2018) Calciphylaxis. N Engl J Med 378(18):1704\u20131714. https:\/\/doi.org\/10.1056\/NEJMra1505292","journal-title":"N Engl J Med"},{"issue":"1","key":"3322_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2008.05.001","volume":"23","author":"R Appelboam","year":"2009","unstructured":"Appelboam R, Thomas EO (2009) Warfarin and intracranial haemorrhage. Blood Rev 23(1):1\u20139. https:\/\/doi.org\/10.1016\/j.blre.2008.05.001","journal-title":"Blood Rev"},{"issue":"1","key":"3322_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.ajkd.2015.01.034","volume":"66","author":"SU Nigwekar","year":"2015","unstructured":"Nigwekar SU et al (2015) Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis 66(1):133\u2013146. https:\/\/doi.org\/10.1053\/j.ajkd.2015.01.034","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3322_CR57","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","volume":"38","author":"A Amin","year":"2014","unstructured":"Amin A et al (2014) Estimation of the impact of warfarin\u2019s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis 38(2):150\u2013159. https:\/\/doi.org\/10.1007\/s11239-013-1048-z","journal-title":"J Thromb Thrombolysis"},{"issue":"9921","key":"3322_CR58","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"issue":"23","key":"3322_CR59","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","volume":"147","author":"J Harrington","year":"2023","unstructured":"Harrington J et al (2023) Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF. Circulation 147(23):1748\u20131757. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062752","journal-title":"Circulation"},{"issue":"17","key":"3322_CR60","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","volume":"74","author":"S Kumar","year":"2019","unstructured":"Kumar S et al (2019) Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol 74(17):2204\u20132215. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1031","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"3322_CR61","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","volume":"33","author":"SH Hohnloser","year":"2012","unstructured":"Hohnloser SH et al (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur. Heart J. 33(22):2821\u20132830. https:\/\/doi.org\/10.1093\/eurheartj\/ehs274","journal-title":"Eur. Heart J."},{"issue":"17","key":"3322_CR62","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","volume":"141","author":"JW Stanifer","year":"2020","unstructured":"Stanifer JW et al (2020) Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 141(17):1384\u20131392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044059","journal-title":"Circulation"},{"issue":"4","key":"3322_CR63","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejh.13383","volume":"104","author":"B Miao","year":"2020","unstructured":"Miao B, Sood N, Bunz TJ, Coleman CI (2020) Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. Eur. J. Haematol. 104(4):328\u2013335. https:\/\/doi.org\/10.1111\/ejh.13383","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"3322_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2021.10.023","volume":"79","author":"P Osmancik","year":"2022","unstructured":"Osmancik P et al (2022) 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol 79(1):1\u201314. https:\/\/doi.org\/10.1016\/j.jacc.2021.10.023","journal-title":"J Am Coll Cardiol"},{"key":"3322_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/pace.15208","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K et al (2025) Optimal thromboembolism prevention for patients with atrial fibrillation on long-term dialysis. Pacing Clin Electrophysiol. https:\/\/doi.org\/10.1111\/pace.15208","journal-title":"Pacing Clin Electrophysiol"},{"issue":"19","key":"3322_CR66","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.112.099606","volume":"126","author":"BA Goldstein","year":"2012","unstructured":"Goldstein BA, Arce CM, Hlatky MA, Turakhia M, Setoguchi S, Winkelmayer WC (2012) Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 126(19):2293\u20132301. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.099606","journal-title":"Circulation"},{"issue":"2","key":"3322_CR67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2010050459","volume":"22","author":"WC Winkelmayer","year":"2011","unstructured":"Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J. Am. Soc. Nephrol. 22(2):349\u2013357. https:\/\/doi.org\/10.1681\/ASN.2010050459","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"3322_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.70094","volume":"41","author":"T-Y Chang","year":"2025","unstructured":"Chang T-Y et al (2025) Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation and kidney failure under hemodialysis: a meta-analysis of controlled randomized trials. Journal of Arrhythmia 41(3):e70094. https:\/\/doi.org\/10.1002\/joa3.70094","journal-title":"Journal of Arrhythmia"},{"key":"3322_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/10760296241271423","volume":"30","author":"M Xiong","year":"2024","unstructured":"Xiong M, Guo L, Wan Y (2024) Factor Xa inhibitors versus vitamin K antagonists in atrial fibrillation patients with end-stage kidney disease on dialysis: A meta-analysis. Clin Appl Thromb Hemost 30:10760296241271424. https:\/\/doi.org\/10.1177\/10760296241271423","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03322-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:36:55Z","timestamp":1791743815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03322-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":69,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03322-3","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors\u2019 consent has been obtained by the corresponding author for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors received payments or services via his or her institution or from third parties.","order":3,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}